Adriatic is the new Pacific as durva improves PFS and OS in LS-SCLC! So proud of my mentor Prof. Suresh Senan who lead this effort - lots to unpack here on PCI, RT schedule, and choice of platinum chemo #LCSM#RadOnc@drdavidpalma@bslotman@_ShankarSiva@DrewMoghanaki
Insightful discussion by @gerryhanna on 4 studies exploring the intensification of both surgical and non-surgical treatments for stage 3 NSCLC in the IO era
➡️ Provocative findings, though phase 3 data will be crucial
➡️ Urgent need for predictive biomarkers
#WCLC24
TOMORROW‼️‼️👀👀
If you are a medical student interested in learning more about Moffitt Rad Onc, please sign up at the link below.
Sign up link: https://t.co/V12b26KoZ4
Now accepting volunteers interested in serving on committees &/or subcommittees for the Society year beginning 10/1. Read this ASTROblog post feat. President-elect @SameerKeoleMD, where he encourages members to think of how one can volunteer for the field. https://t.co/FsmrS3C4lL
I research women and far-right movements in the U.S. and Europe, including why women are increasingly likely to join and how their role has changed. This speech was a masterclass. 1/
@ielnaqa, @tom_dilling and Denis Dudas recently produced a publication entitled: "Improved outcome models with denoising diffusion" Please click here to see a copy of this publication:
https://t.co/oCzaJAiwFe
@sueyom The best data on OMD is the AJCC 8th edition pt dataset. Oligomet = 1 site (M1a). TWO sites = M1b. In other words, I’m not surprised (though saddened to see confirmed). Also, some early studies included oligometastatic and also oligoprogressive pts….
@ml4onco congratulates @GhasemiPayman, @tom_dilling, @SA_Rosenberg and @ielnaqa on their newest publication: "Novel Dose Criteria for Lung Cancer SBRT to Improve Local Control in Patients Treated to 50 Gy/5 Fractions Using Deep Learning Methods..." https://t.co/bbXjBj7wFw